Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Dec. 31, 2017 | Feb. 19, 2018 | |
Document And Entity Information | ||
Entity Registrant Name | Rich Pharmaceuticals, Inc. | |
Entity Central Index Key | 1,504,389 | |
Document Type | 10-Q | |
Document Period End Date | Dec. 31, 2017 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --03-31 | |
Is Entity a Well-known Seasoned Issuer? | No | |
Is Entity a Voluntary Filer? | No | |
Is Entity's Reporting Status Current? | Yes | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 1,215,437,821 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2,018 |
Balance Sheets
Balance Sheets - USD ($) | Dec. 31, 2017 | Mar. 31, 2017 |
Current Assets | ||
Cash and equivalents | $ 3,743 | $ 40,903 |
Notes receivable | 15,300 | 10,000 |
Total Current Assets | 19,043 | 50,903 |
Property and equipment, net | 1,225 | 2,125 |
Securities available for sale | 15,000 | |
TOTAL ASSETS | 35,268 | 53,028 |
Current Liabilities | ||
Accounts payable | 352,107 | 296,635 |
Accounts payable related party | 376,950 | 53,000 |
Accrued expenses | 1,360,810 | 937,783 |
Due to related parties | 37,024 | 49,395 |
Note payable | 920,000 | 920,000 |
Convertible notes payable, net of debt discount of $90,186 and $356,819 | 838,514 | 514,075 |
Derivative liabilities | 1,360,706 | 2,607,959 |
Total Current Liabilities | 5,246,111 | 5,378,847 |
Total Liabilities | 5,246,111 | 5,378,847 |
Commitments and Contingencies | ||
Stockholders Deficit | ||
Preferred stock, $.001 par value, 10,000,000 shares authorized, 6,000,000 shares issued and outstanding, respectively | 6,000 | 6,000 |
Common stock, $0.001 par value, 2,000,000,000 shares authorized, 955,027,813 and 101,446,215 shares issued and outstanding, | 955,024 | 101,446 |
Common stock to be issued | 100,000 | |
Additional paid-in capital | 6,623,186 | 7,011,504 |
Accumulated deficit | (12,895,053) | (12,444,769) |
Total Stockholders Deficit | (5,210,843) | (5,325,819) |
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT | $ 35,268 | $ 53,028 |
Balance Sheets (Parenthetical)
Balance Sheets (Parenthetical) - USD ($) | Dec. 31, 2017 | Mar. 31, 2017 |
Statement of Financial Position [Abstract] | ||
Common Stock, Par Value | $ .001 | $ .001 |
Common Stock, Shares Authorized | 2,000,000,000 | 2,000,000,000 |
Common Stock, Issued | 955,027,813 | 101,446,215 |
Preferred Stock, Par Value | $ .001 | $ .001 |
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 |
Preferred Stock, Issued | 6,000,000 | 6,000,000 |
Convertible notes payable, debt discount | $ 90,186 | $ 356,819 |
Statements of Operations
Statements of Operations - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | |
Income Statement [Abstract] | ||||
REVENUES | $ 115,000 | |||
OPERATING EXPENSES | ||||
Consulting expenses | 21,625 | 10,325 | 121,625 | 26,400 |
Office expenses | 56,279 | 24,612 | 154,510 | 94,658 |
Depreciation expense | 313 | 431 | 899 | 1,293 |
Wages and taxes | 136,941 | 95,955 | 414,693 | 287,911 |
Professional fees | 15,027 | 57,525 | 119,726 | 145,926 |
Regulatory fees | 2,656 | (1,664) | 41,147 | 7,865 |
Research and development | 92,750 | 241,156 | ||
Travel, meals and entertainment | 8,128 | 21,632 | 42,901 | 43,035 |
TOTAL OPERATING EXPENSES | 333,719 | 208,816 | 1,136,657 | 607,088 |
LOSS FROM OPERATIONS | (333,719) | (208,816) | (1,021,657) | (607,088) |
OTHER INCOME (EXPENSE) | ||||
Amortization of debt discount | (174,119) | (33,006) | (855,130) | (105,366) |
Change in value of derivative liability | 691,707 | (84,508) | 1,760,172 | 83,946 |
Derivative expense | (78,350) | (170,250) | (327,807) | (170,250) |
Interest expense | (50,013) | (43,715) | (218,695) | (186,189) |
Interest expense related party | (155) | (155) | (463) | (385) |
Gain (Loss) on extinguishment of debt | 213,294 | (9,584) | ||
TOTAL OTHER INCOME EXPENSES | 389,070 | (331,634) | 571,371 | (378,244) |
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES | 55,351 | (540,450) | (450,286) | (985,332) |
PROVISION FOR INCOME TAXES | ||||
NET INCOME (LOSS) | $ 55,351 | $ (540,450) | $ (450,286) | $ (985,332) |
NET INCOME (LOSS) PER SHARE: BASIC AND DILUTED | $ 0 | $ 0 | $ 0 | $ 0 |
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED | 952,724,596 | 41,915,634 | 583,678,904 | 30,560,809 |
Statements of Cash Flows
Statements of Cash Flows - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Mar. 31, 2017 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||
Net loss for the period | $ 55,351 | $ (540,450) | $ (450,286) | $ (985,332) | |
Adjustments to reconcile net loss to net cash used in operating activities | |||||
Depreciation expense | 313 | 431 | 899 | 1,293 | $ 1,606 |
Amortization of debt discount | 174,119 | 33,006 | 855,130 | 105,366 | |
Change in value of derivative liability | (691,707) | 84,508 | (1,760,172) | (83,946) | |
Derivative expense | 78,350 | 170,250 | 327,807 | 170,250 | |
Gain on extinguishment of debt | (213,294) | 9,584 | |||
Changes in operating assets and liabilities: | |||||
Decrease in prepaid expenses | 2,800 | ||||
Increase (decrease) in bank overdraft | (2,543) | ||||
Increase in accounts payable | 379,423 | 127,133 | |||
Increase in accrued expenses | 490,846 | 366,464 | |||
Net Cash Used by Operating Activities | (369,647) | (288,931) | |||
CASH FLOWS FROM INVESTING ACTIVITY: | |||||
Increase in notes receivable | (5,300) | ||||
Increase in stock held for investment | (15,000) | ||||
Net Cash Used by Investing Activities | (20,300) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||
Loans received (repaid) from/to related parties | (12,371) | (27,319) | |||
Proceeds from sale of common stock and warrants | 100,000 | ||||
Proceeds from issuance of convertible notes payable | 265,158 | 316,250 | |||
Net Cash Provided by Financing Activities | 352,787 | 288,931 | |||
Net Increase (Decrease) in Cash and Cash Equivalents | (37,160) | ||||
Cash and cash equivalents, beginning of period | 40,903 | ||||
Cash and cash equivalents, end of period | $ 3,743 | 3,743 | $ 40,903 | ||
SUPPLEMENTAL CASH FLOW INFORMATION: | |||||
Interest paid | |||||
Income taxes paid | |||||
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION: | |||||
Accounts payable converted into note payable | 900,000 | ||||
Warrants issued for accrued expenses | |||||
Original issue discounts recorded on notes payable | 6,850 | ||||
Debt discounts recorded on convertible notes payable | 581,647 | 147,632 | |||
Debt/interest converted into common stock and contributed capital | $ 295,721 | $ 109,144 |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Dec. 31, 2017 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Nature of Business On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 265,646 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 250,128 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 131,261 common shares. (All shares stated at post-split amounts.) On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At December 31, 2017 and March 31, 2017 the Company had $3,743 and $40,903, respectively, of unrestricted cash. Basis of Presentation The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These condensed financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017, as filed with the U.S. Securities and Exchange Commission. Property and Equipment Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. Long-Lived and Intangible Assets The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at December 31, 2017 or March 31, 2017. As of December 31, 2017, the derivative liabilities were considered a level 2 item; see Note 9 . The Company has securities available for sale which are not evaluated using the above hierarchy due to common control issues, these securities are carried at the transaction price. (See Note 3) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Revenue Recognition The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. Research and Development The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes. Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 195,002 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 9,875 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 195,000 stock options to officers, directors, employees and consultants. During the period ended March 31, 2017, the Company granted 29,000,000 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $3.40; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $1.60 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.20 per share. (All shares are stated at post-split amounts). Basic Loss Per Share The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Total potentially dilutive instruments are: 9,446,533 common share warrants, and 29,228,627 common shares upon exercise of outstanding options. In periods of net losses the dilutive loss per share is the same as the basic loss per share because the effect of the dilutive shares in periods of loss is antidilutive. Recent Accounting Pronouncements The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow. |
Property and equipment
Property and equipment | 9 Months Ended |
Dec. 31, 2017 | |
Property, Plant and Equipment [Abstract] | |
Property and equipment | Property and equipment, recorded at cost, consisted of the following as of December 31, 2017 and March 31, 2017: December 31, 2017 March 31, 2017 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (3,935 ) (3,035 ) Property and equipment, net $ 1,225 $ 2,125 The useful life of the computer equipment and furniture is 3 years. Depreciation expense was $899 and $1,606 for the periods ended December 31, 2017 and March 31, 2017, respectively. |
Securities Available For Sale
Securities Available For Sale | 9 Months Ended |
Dec. 31, 2017 | |
Investments, Debt and Equity Securities [Abstract] | |
Securities Available For Sale | The Company received 15,000,000 common stock shares of an entity that is majority owned by a non-majority stockholder of the Company as partial payment for access to the Company’s intellectual property. This holding represents about 11% of the ownership of the invested company. The Company classifies its equity securities held as available for sale, and as such, they are carried at fair value. Changes in fair value of available for sale securities will be reported as a component of other comprehensive income and evaluated at the end of each quarter. The shares currently do not have a firm trading price and thus they are carried at their par value until such time as the shares have established a trading price in the market. |
Intangible Assets
Intangible Assets | 9 Months Ended |
Dec. 31, 2017 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets | On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 110,396 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0. |
Accrued Expenses
Accrued Expenses | 9 Months Ended |
Dec. 31, 2017 | |
Payables and Accruals [Abstract] | |
Accrued Expenses | Accrued expenses consisted of the following as of December 31, 2017 and March 31, 2017: December 31, 2017 March 31, 2017 Wages and taxes $ 1,140,040 $ 829,231 Accrued interest 220,770 108,552 Total accrued expenses $ 1,360,810 $ 937,783 |
Related Party Debt and Transact
Related Party Debt and Transactions | 9 Months Ended |
Dec. 31, 2017 | |
Related Party Transactions [Abstract] | |
Related Party Debt and Transactions | During the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. During the period ended March 31, 2017 the Company received an additional $6,280 from this related party. The loan is unsecured and bears 8% interest and has an original due date of January 8, 2016. There is a total due of $12,280 as of December 31, 2017 and March 31, 2017. Interest accrued on the note as of December 31, 2017 was $1,366. The Company is in default on the balance of this note. During the period ending March 31, 2016, the Company received $22,200 in unsecured non-interest bearing loans from related parties and during the period ending March 31, 2017 received an additional $14,450, and has repaid $36,300 of these loans leaving a total due of $350 as of December 31, 2017. These loans are deemed to be short-term and are payable at the discretion of the Company. Periodically, related parties incur expenses for the Company and are expected to be repaid for those expenditures. As of December 31, 2017, the balance owed to related parties for these types of expenses is $23,029. These liabilities do not have stated interest rates or due dates, but are payable at the discretion of the Company. The Company has a consulting agreement with a related party to provide research into new technologies as well as essential development of current products. The amounts owed to this related party for past work is a part of accounts payable and totals $376,950 and $53,000 for the periods ending December 31, 2017 and March 31, 2017, respectively. On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years, and has been extended for an additional two years; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 1,500 shares of common stock at an exercise price of $40.00 per share. The CEO earned $206,250 and $275,000 for the nine months ended December 31, 2017 and the twelve months ended March 31, 2017 (respectively) as a result of this agreement, these amounts contribute to the $806,361 and $645,945 of officer compensation which is included in accrued expenses, as of December 31, 2017 and March 31, 2017. The Company received $100,000 cash and 15,000,000 common stock shares of an entity that is majority owned by a non-majority stockholder of the Company as partial payment for access to the Company’s intellectual property. This receipt is classified as income in the period it was earned. (See Note 3) |
Note Payable
Note Payable | 9 Months Ended |
Dec. 31, 2017 | |
Debt Disclosure [Abstract] | |
Note Payable | On May 31, 2016, the Company issued a secured promissory note in the amount of $900,000. The note is due on August 1, 2017 and bears interest at 10% per annum. The loan replaced an account payable to a legal professional to cover past due amounts and penalties for non-payment. The note is guaranteed personally by two shareholders and collateralized by assets of the company and guarantors. Accrued interest was $142,767 as of December 31, 2017. On February 21, 2017, the Company issued a non-secured promissory note in the amount of $20,000. The note is due on August 21, 2017 and bears interest at 8% per annum. The loan was in payment for professional fees related to an equity financing agreement dated February 21, 2017, thus no cash was received by the Company. Accrued interest was $1,372 as of December 31, 2017. |
Convertible Note Payable
Convertible Note Payable | 9 Months Ended |
Dec. 31, 2017 | |
Debt Disclosure [Abstract] | |
Convertible Note Payable | On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 619,652 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. On February 22, 2017, this note was purchased for a renegotiated face value of $59,799, incurring additional financing fees of $11,819. (details are provided under the note dated February 22, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and was originally due on December 9, 2015, with a revised due date of June 23, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 2,886,693 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,377 in principal and $422 in accrued interest into 2,324,229 shares of common stock leaving a remaining balance of $ 8,838. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) days prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 796,236 shares of common stock leaving a remaining balance of $18,751. The Company is in default on the balance of this note. On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 906,763 shares of common stock. During the period ending March 31, 2017 the note holder converted $60,439 in principal and $6,839 in accrued interest into 44,551,004 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of . On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of . On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending the note holder converted $15,000 in principal and $939 in accrued interest into 4,351,619 shares of common stock leaving a remaining balance of $0. On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and was originally due on December 30, 2016 , The loan becomes convertible on , 2015, the issue date of the note. The loan can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 1,796,394 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period prior to the conversion date. On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date.. During the period ending the note holder converted $16,745 in principal and $1,380 in interest into 3,325,000 shares of common stock leaving a remaining balance of $10,755. On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. On June 8, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250. The note bears interest at the rate of 8% and must be repaid on or before June 8, 2017. The note and any accrued interest may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. On February 20, 2017, this note was consolidated with other outstanding convertible notes and purchased for a renegotiated face value of $134,214, incurring additional financing fees of $49,964. (details are provided under the note dated February 20, 2017 below). As of March 31, 2017 the principal and accrued interest balance is $0. On June 23, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or before June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. As of December 31, 2017 the accrued interest balance is $6,824. The Company is in default on this note. On July 7, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or before July 7, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, . On October 20, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $32,000. The note bears interest at the rate of 8% and must be repaid on or before October 20, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On November 17, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or before June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On January 5, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $335,000. The note bears interest at the rate of 10%, contains a $30,000 OID, and must be repaid by October 5, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or January 5, 2017, On February 20, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $563,028 which is partially funded, the current balance consolidates unpaid convertible notes dated March 9, 2015; September 4, 2015; December 29, 2015; February 25, 2016; March 24, 2016; May 25, 2016; June 8, 2016; June 23, 2016; July 7, 2016; October 20, 2016; November 17, 2016. The note bears interest at the rate of 8%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 20, 2017, On February 21, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $15,000. The note bears interest at the rate of 8%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 21, 2017, On February 22, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $59,799, which refinances an unpaid convertible note dated February 5, 2015. The note bears interest at the rate of 10%, and must be repaid by October 25, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 22, 2017, On February 22, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $20,900, which refinances an unpaid convertible note dated May 6, 2015. The note bears interest at the rate of 10%, and must be repaid by October 22, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or February 22, 2017, On April 4, 2017, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $71,457, which refinances an unpaid convertible note dated January 22, 2016. The note bears interest at the rate of 8%, and must be repaid by January 4, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or , On April 18, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $115,000. The note bears interest at the rate of 10%, a 10% original issue discount and the lender will hold $5000 to cover transaction costs, the note must be repaid by January 30, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or , On November 3, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $34,500. The note bears interest at the rate of 10%, a 10% original issue discount and the lender will hold $1,500 to cover transaction costs, the note must be repaid by August 3, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or , On December 18, 2017, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $43,850. The note bears interest at the rate of 10%, a 10% original issue discount and the lender will hold $1,500 to cover transaction costs, the note must be repaid by September 18, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or , |
Derivative Liabilities
Derivative Liabilities | 9 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Derivative Liabilities | In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date. As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the periods ending December 31, 2017 and March 31, 2017: $29,680 note dated March 26, 2015; $60,500 note dated January 22, 2016 $56,000 note dated June 23, 2016; $58,000 note dated July 7, 2016; $32,000 note dated October 20, 2016; $56,000 note dated November 17, 2016; $335,000 note dated January 5, 2017; $563,028 note dated February 20, 2017; $15,000 note dated February 21, 2017; $59,799 note dated February 22, 2017; $20,900 note dated February 22, 2017; $71,457 note dated April 4, 2017; $115,000 note dated April 18, 2017; $34,500 note dated November 3, 2017; $43,850 note dated December 18, 2017. ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt. During the period ended December 31, 2017, the Company recorded a total change in the fair market value of the derivative liabilities of $1,760,172. The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period. Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.0005-$0.0005, exercise price of $0.0003 - $0.0002, dividend yield of zero, years to maturity of 0.01096 – .58904, a risk free rate of 1.28% - 1.76%, and annualized volatility of 22% - 603%. The above loans were all discounted in full. Based on the valuations on the initial valuation dates for the period ending December 31, 2017, the Company recognized debt discounts related to the conversion features totaling $855,130 and a derivative expense of $327,807 related to the excess value of the derivative liabilities. Once the loans are fully converted, the remaining derivative liability is reclassified to equity as additional paid-in capital. As of December 31, 2017, unamortized debt discount, including original issue discounts totaled $90,186. The derivative liabilities totaled $1,360,706 as of December 31, 2017, of which $- related to long-term debt. |
Equity Transactions
Equity Transactions | 9 Months Ended |
Dec. 31, 2017 | |
Equity Transactions | |
Equity Transactions | The Company has 2,000,000,000 common shares authorized with a par value of $ 0.001 per share. The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date March 30, 2017 Warrants 9,200,000 Stock price on grant date $0.002 Exercise price $0.002 Expected life 5 year Volatility 120% Risk-free rate 1.96% Calculated value $15,278 Fair value allocation of proceeds $45,466 The following is a summary of the warrant activity for the period March 31, 2017 to December 31, 2017 : Number of warrants Weighted average exercise price Outstanding, March 31, 2017 9,446,533 $0.102 Granted - - Exercised - - Outstanding, December 31, 2017 9,446,533 $0.102 Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. During the period ended December 31, 2017, the Company issued common stock to satisfy convertible debt conversions at a price below par value as obligated by contract. During this period the Company issued 853,580,551 common shares at a below par rate, incurring an adjustment to additional paid in capital of $557,863. During August 2017, the Company received $100,000 from a related party as consideration for a stock subscription agreement dated October 16, 2017. The agreement stipulates issuance of 333,333,333 common stock and an additional warrants to purchase another 333,333,333 common shares at $0.0003 per share for a five year term. As of December 31, 2017, the Company has available shares to fulfill this obligation but are awaiting the transfer agent’s instructions, thus the $100,000 collected on this agreement is recorded as common stock to be issued in the financial statements until such instructions become available to complete this transaction. During the period ended March 31, 2017, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $2,197 488,316 $ 0.00450 April 4, 2016 $4,847 862,500 $ 0.00562 April 7, 2016 $1,750 486,111 $ 0.00360 April 14, 2016 $4,158 962,500 $ 0.00432 April 15, 2016 $1,318 488,311 $ 0.00270 April 26, 2016 $1,705 631,489 $ 0.00270 May 4, 2016 $2,067 485,901 $ 0.00426 May 31, 2016 $ 828 230,003 $ 0.00360 June 2, 2016 $9,120 1,500,000 $ 0.00608 June 2, 2016 $4,401 1,467,017 $ 0.00300 June 14, 2016 $5,847 1,461,795 $ 0.00400 June 17,2016 $5,691 1,422,808 $ 0.00400 June 29, 2016 $6,580 1,063,518 $ 0.00618 August 23, 2016 $2,567 1,106,487 $ 0.00232 August 29, 2016 $2,570 1,107,806 $ 0.00232 September 6, 2016 $2,547 1,097,634 $ 0.00232 September 20, 2016 $2,443 1,263,383 $ 0.00194 September 26, 2016 $2,946 1,269,672 $ 0.00232 September 28, 2016 $2,947 1,270,172 $ 0.00232 September 30, 2016 $3,949 2,553,336 $ 0.00154 October 7, 2016 $3,381 2,914,578 $ 0.00116 October 14, 2016 $3,380 2,913,784 $ 0.00116 October 21, 2016 $3,385 2,917,784 $ 0.00116 October 26, 2016 $3,382 2,915,828 $ 0.00116 October 31, 2016 $5,037 4,341,852 $ 0.00116 November 7 , 2016 $5,015 4,323,647 $ 0.00116 November 22, 2016 $5,513 4,753,008 $ 0.00116 November 29, 2016 $5,515 4,754,647 $ 0.00116 December 6, 2016 $4,058 3,497,965 $ 0.00116 January 10, 2017 $6,301 6,301,150 $ 0.00100 February 22, 2017 $4,290 3,575,000 $ 0.00120 March 13, 2017 $4,080 3,400,000 $ 0.00120 March 21, 2017 $4,920 4,100,000 $ 0.00120 March 22, 2017 $5,160 4,300,000 $ 0.00120 March 24, 2017 $5,460 4,550,000 $ 0.00120 March 30, 2017 $5,645 4,800,000 $ 0.00118 March 31, 2017 $5,939 5,050,000 $ 0.00118 March 31, 2017 Total $150,939 90,628,002 During the period ended December 31, 2017 , the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share April 5, 2017 $6,233 5,300,000 $0.00118 April 10, 2017 $6,586 5,600,000 $0.00118 April 11, 2017 $6,880 5,850,000 $0.00118 April 18, 2017 $7,291 6,200,000 $0.00118 April 20, 2017 $7,644 6,500,000 $0.00118 April 21, 2017 $16,464 14,000,000 $0.00118 April 25, 2017 $17,287 14,700,000 $0.00118 April 26, 2017 $26,600 26,600,000 $0.00100 May 1, 2017 $8,700 14,500,000 $0.00060 June 13, 2017 $1,200 10,000,000 $0.00012 June 16, 2017 $1,930 19,299,400 $0.00010 June 16, 2017 $1,300 11,000,000 $0.00012 June 20, 2017 $1,392 11,600,000 $0.00012 June 21, 2017 $2,314 23,139,900 $0.00010 June 22, 2017 $1,590 13,250,000 $0.00012 June 22, 2017 $1,470 12,250,000 $0.00012 June 26, 2017 $1,800 15,000,000 $0.00012 June 29, 2017 $1,980 16,500,000 $0.00012 July 3, 2017 $2,088 17,400,000 $0.00012 July 12, 2017 $2,088 17,400,000 $0.00012 July 13, 2017 $2,484 13,800,000 $0.00018 July 14, 2017 $3,374 19,000,000 $0.00018 July 18, 2017 $3,374 19,000,000 $0.00018 July 20, 2017 $3,582 19,900,000 $0.00018 July 24, 2017 $6,270 20,900,000 $0.0003 July 25, 2017 $6,870 22,900,000 $0.0003 July 28, 2017 $7,200 24,000,000 $0.0003 August 2, 2017 $7,200 24,000,000 $0.0003 August 4, 2017 $9,000 25,000,000 $0.00036 August 8, 2017 $11,119 26,475,000 $0.00042 August 11, 2017 $13,920 29,000,000 $0.00048 August 16, 2017 $12,810 30,500,000 $0.00042 August 22, 2017 $6,709 19,168,058 $0.00035 August 25, 2017 $11,200 32,000,000 $0.00035 August 31, 2017 $9,600 32,000,000 $0.0003 September 7, 2017 $9,900 36,000,000 $0.00028 September 15, 2017 $9,437 37,900,000 $0.00025 September 22, 2017 $9,910 39,800,000 $0.00025 September 28, 2017 $10,408 41,800,000 $0.00025 October 3, 2017 $10,931 43,900,000 $0.00025 October 5, 2017 $7,582 30,448,193 $0.00025 December 31, 2017 Total $295,717 853,580,551 (2) Effective April 6, 2015, the Company approved the re-pricing of all 135,627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.60 per share and $3.40 per share, to $1.60 per share which was the closing price of the Company’s common stock on April 6, 2015. All of the other terms of the options remained unchanged. (3) Effective August 4, 2015, the Company approved the re-pricing of all 185.627 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.60 per share and $0.40 per share, to $0.40 per share which was the closing price of the Company’s common stock on August 4, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 and again on April 6, 2015, and again on August 4, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 on January 9, 2015 and an additional $9,316 on April 6, 2015, and an additional $47,463 on August 4, 2015 in related stock based compensation expense for those periods. The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model. Date April 6, 2015 June 9, 2015 December 15, 2015 March 30, 2017 Options 102,000 50,000 43,000 29,000,000 Stock price grant date $1.60 $0.40 $0.20 $0.002 Initial Exercise price $1.60 $0.40 $0.20 $0.002 Modified Exercise price $0.20 $0.20 $0.20 - Expected life 5.0 5.0 5.0 5.0 Volatility 99% 99% 84% 120% Risk-free rate 1.31% 1.74% 1.70% 1.93% Calculated value $120,778 $14,838 $5,736 $48,017 Modified value $151,221 $16,347 $5,736 $48,017 The following is a summary of the option activity for the period March 31, 2017 through December 31, 2017: Number of options Weighted average exercise price Outstanding, March 31, 2017 29,228,627 $0.004 Granted - - Exercised - - Expired - - Outstanding, December 31, 2017 29,228,627 $0.004 The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined. |
Commitments and Contigencies
Commitments and Contigencies | 9 Months Ended |
Dec. 31, 2017 | |
Accounting Policies [Abstract] | |
Commitments and Contingencies | The Company leases office space on a verbal month-to-month agreement. Monthly rent is about $2,800. On July 8, 2016, the Company engaged a foreign based company to evaluate the safety and efficacy of RP-323 over a 27 month period. The contract stipulates a commitment of $193,255 with additional fees for pass-through expenses. The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court. The Company incurred substantial fees in defending the litigation. On April 1, 2017, the Company entered into a tentative agreement with CannCodex to issue 78,000,000 common shares of stock in exchange for data base assets of CannCodex. However, this agreement was not finalized and subsequently the Company is not responsible for issuance of the stock. Unrelated to this agreement, the Company has issued short-term loans to CannCodex totaling $15,300 as of December 31, 2017 |
Liquidity and Going Concern
Liquidity and Going Concern | 9 Months Ended |
Dec. 31, 2017 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Liquidity and Going Concern | The Company has a working capital deficit, has not yet received significant revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the Company’s ability to continue as a going concern for the twelve months following the date that these financial statements were issued. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts. |
Subsequent Events
Subsequent Events | 9 Months Ended |
Dec. 31, 2017 | |
Accounting Policies [Abstract] | |
Subsequent Events | On January 10, 2018, the Company issued a 10% Convertible Redeemable Promissory Note in the principal amount of $67,500. The note bears interest at the rate of 10%, a 10% original issue discount and the lender will hold $1,500 to cover transaction costs, the note must be repaid by October 10, 2018. The note and any accrued interest may be converted by lender into shares of Company common stock, upon execution or , Subsequent to the period ended December 31, 2017, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share January 2, 2018 $9,530 47,650,000 $0.0002 January 12, 2018 $10,000 50,000,000 $0.0002 January 18, 2018 $9,875 50,000,000 $0.0002 January 24, 2018 $8,250 55,000,000 $0.00015 February 1, 2018 $7,220 57,760,000 $0.000125 Subsequent Total $44,875 260,410,000 In accordance with ASC 855-10, the Company has analyzed its operations subsequent to December 31, 2017 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above. |
Summary of Significant Accoun19
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Dec. 31, 2017 | |
Accounting Policies [Abstract] | |
Nature of Business | On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 265,646 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 250,128 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 131,261 common shares. (All shares stated at post-split amounts.) On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Effective June 7, 2017, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 20 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. |
Cash and Cash Equivalents | The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At December 31, 2017 and March 31, 2017 the Company had $3,743 and $40,903, respectively, of unrestricted cash. |
Basis of Presentation | The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These condensed financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017, as filed with the U.S. Securities and Exchange Commission. |
Property and Equipment | Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. |
Long-Lived and Intangible Assets | On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 41,384 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 110,396 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0. |
Fair Value of Financial Instruments | The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at December 31, 2017 or March 31, 2017. As of December 31, 2017, the derivative liabilities were considered a level 2 item; see Note 9. The Company has securities available for sale which are not evaluated using the above hierarchy due to common control issues, these securities are carried at the transaction price. (See Note 3) |
Use of Estimates | The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. |
Income Taxes | Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. |
Revenue Recognition | The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. |
Research and Development | The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes. |
Stock-Based Compensation | Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 195,002 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 9,875 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 195,000 stock options to officers, directors, employees and consultants. During the period ended March 31, 2017, the Company granted 29,000,000 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $3.40; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $1.60 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.20 per share. (All shares are stated at post-split amounts). |
Basic loss per share | The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Total potentially dilutive instruments are: 9,446,533 common share warrants, and 29,228,627 common shares upon exercise of outstanding options. In periods of net losses the dilutive loss per share is the same as the basic loss per share because the effect of the dilutive shares in periods of loss is antidilutive. |
Recent Accounting Pronouncements | The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow. |
Property and equipment (Tables)
Property and equipment (Tables) | 9 Months Ended |
Dec. 31, 2017 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property and Equipment | December 31, 2017 March 31, 2017 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (3,935 ) (3,035 ) Property and equipment, net $ 1,225 $ 2,125 |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 9 Months Ended |
Dec. 31, 2017 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Expenses | December 31, 2017 March 31, 2017 Wages and taxes $ 1,140,040 $ 829,231 Accrued interest 220,770 108,552 Total accrued expenses $ 1,360,810 $ 937,783 |
Equity Transactions (Tables)
Equity Transactions (Tables) | 1 Months Ended | 9 Months Ended | 12 Months Ended |
Feb. 01, 2018 | Dec. 31, 2017 | Mar. 31, 2017 | |
Accounting Policies [Abstract] | |||
Schedule of Value of Warrants | Date March 30, 2017 Warrants 9,200,000 Stock price on grant date $0.002 Exercise price $0.002 Expected life 5 year Volatility 120% Risk-free rate 1.96% Calculated value $15,278 Fair value allocation of proceeds $45,466 | ||
Schedule of Warrant Activity | Number of warrants Weighted average exercise price Outstanding, March 31, 2017 9,446,533 $0.102 Granted - - Exercised - - Outstanding, December 31, 2017 9,446,533 $0.102 | ||
Schedule of Conversions of Common Stock | Date Debt/Interest Converted Common Stock Issued Price per Share January 2, 2018 $9,530 47,650,000 $0.0002 January 12, 2018 $10,000 50,000,000 $0.0002 January 18, 2018 $9,875 50,000,000 $0.0002 January 24, 2018 $8,250 55,000,000 $0.00015 February 1, 2018 $7,220 57,760,000 $0.000125 Subsequent Total $44,875 260,410,000 | Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $2,197 488,316 $ 0.00450 April 4, 2016 $4,847 862,500 $ 0.00562 April 7, 2016 $1,750 486,111 $ 0.00360 April 14, 2016 $4,158 962,500 $ 0.00432 April 15, 2016 $1,318 488,311 $ 0.00270 April 26, 2016 $1,705 631,489 $ 0.00270 May 4, 2016 $2,067 485,901 $ 0.00426 May 31, 2016 $ 828 230,003 $ 0.00360 June 2, 2016 $9,120 1,500,000 $ 0.00608 June 2, 2016 $4,401 1,467,017 $ 0.00300 June 14, 2016 $5,847 1,461,795 $ 0.00400 June 17,2016 $5,691 1,422,808 $ 0.00400 June 29, 2016 $6,580 1,063,518 $ 0.00618 August 23, 2016 $2,567 1,106,487 $ 0.00232 August 29, 2016 $2,570 1,107,806 $ 0.00232 September 6, 2016 $2,547 1,097,634 $ 0.00232 September 20, 2016 $2,443 1,263,383 $ 0.00194 September 26, 2016 $2,946 1,269,672 $ 0.00232 September 28, 2016 $2,947 1,270,172 $ 0.00232 September 30, 2016 $3,949 2,553,336 $ 0.00154 October 7, 2016 $3,381 2,914,578 $ 0.00116 October 14, 2016 $3,380 2,913,784 $ 0.00116 October 21, 2016 $3,385 2,917,784 $ 0.00116 October 26, 2016 $3,382 2,915,828 $ 0.00116 October 31, 2016 $5,037 4,341,852 $ 0.00116 November 7 , 2016 $5,015 4,323,647 $ 0.00116 November 22, 2016 $5,513 4,753,008 $ 0.00116 November 29, 2016 $5,515 4,754,647 $ 0.00116 December 6, 2016 $4,058 3,497,965 $ 0.00116 January 10, 2017 $6,301 6,301,150 $ 0.00100 February 22, 2017 $4,290 3,575,000 $ 0.00120 March 13, 2017 $4,080 3,400,000 $ 0.00120 March 21, 2017 $4,920 4,100,000 $ 0.00120 March 22, 2017 $5,160 4,300,000 $ 0.00120 March 24, 2017 $5,460 4,550,000 $ 0.00120 March 30, 2017 $5,645 4,800,000 $ 0.00118 March 31, 2017 $5,939 5,050,000 $ 0.00118 March 31, 2017 Total $150,939 90,628,002 | Date Debt/Interest Converted Common Stock Issued Price per Share April 5, 2017 $6,233 5,300,000 $0.00118 April 10, 2017 $6,586 5,600,000 $0.00118 April 11, 2017 $6,880 5,850,000 $0.00118 April 18, 2017 $7,291 6,200,000 $0.00118 April 20, 2017 $7,644 6,500,000 $0.00118 April 21, 2017 $16,464 14,000,000 $0.00118 April 25, 2017 $17,287 14,700,000 $0.00118 April 26, 2017 $26,600 26,600,000 $0.00100 May 1, 2017 $8,700 14,500,000 $0.00060 June 13, 2017 $1,200 10,000,000 $0.00012 June 16, 2017 $1,930 19,299,400 $0.00010 June 16, 2017 $1,300 11,000,000 $0.00012 June 20, 2017 $1,392 11,600,000 $0.00012 June 21, 2017 $2,314 23,139,900 $0.00010 June 22, 2017 $1,590 13,250,000 $0.00012 June 22, 2017 $1,470 12,250,000 $0.00012 June 26, 2017 $1,800 15,000,000 $0.00012 June 29, 2017 $1,980 16,500,000 $0.00012 July 3, 2017 $2,088 17,400,000 $0.00012 July 12, 2017 $2,088 17,400,000 $0.00012 July 13, 2017 $2,484 13,800,000 $0.00018 July 14, 2017 $3,374 19,000,000 $0.00018 July 18, 2017 $3,374 19,000,000 $0.00018 July 20, 2017 $3,582 19,900,000 $0.00018 July 24, 2017 $6,270 20,900,000 $0.0003 July 25, 2017 $6,870 22,900,000 $0.0003 July 28, 2017 $7,200 24,000,000 $0.0003 August 2, 2017 $7,200 24,000,000 $0.0003 August 4, 2017 $9,000 25,000,000 $0.00036 August 8, 2017 $11,119 26,475,000 $0.00042 August 11, 2017 $13,920 29,000,000 $0.00048 August 16, 2017 $12,810 30,500,000 $0.00042 August 22, 2017 $6,709 19,168,058 $0.00035 August 25, 2017 $11,200 32,000,000 $0.00035 August 31, 2017 $9,600 32,000,000 $0.0003 September 7, 2017 $9,900 36,000,000 $0.00028 September 15, 2017 $9,437 37,900,000 $0.00025 September 22, 2017 $9,910 39,800,000 $0.00025 September 28, 2017 $10,408 41,800,000 $0.00025 October 3, 2017 $10,931 43,900,000 $0.00025 October 5, 2017 $7,582 30,448,193 $0.00025 December 31, 2017 Total $295,717 853,580,551 |
Schedule of Value of Options | Date April 6, 2015 June 9, 2015 December 15, 2015 March 30, 2017 Options 102,000 50,000 43,000 29,000,000 Stock price grant date $1.60 $0.40 $0.20 $0.002 Initial Exercise price $1.60 $0.40 $0.20 $0.002 Modified Exercise price $0.20 $0.20 $0.20 - Expected life 5.0 5.0 5.0 5.0 Volatility 99% 99% 84% 120% Risk-free rate 1.31% 1.74% 1.70% 1.93% Calculated value $120,778 $14,838 $5,736 $48,017 Modified value $151,221 $16,347 $5,736 $48,017 | ||
Schedule of Option Activity | Number of options Weighted average exercise price Outstanding, March 31, 2017 29,228,627 $0.004 Granted - - Exercised - - Expired - - Outstanding, December 31, 2017 29,228,627 $0.004 |
Subsequent Events (Tables)
Subsequent Events (Tables) | 1 Months Ended | 9 Months Ended | 12 Months Ended |
Feb. 01, 2018 | Dec. 31, 2017 | Mar. 31, 2017 | |
Subsequent Events Tables | |||
Schedule of Conversions of Common Stock | Date Debt/Interest Converted Common Stock Issued Price per Share January 2, 2018 $9,530 47,650,000 $0.0002 January 12, 2018 $10,000 50,000,000 $0.0002 January 18, 2018 $9,875 50,000,000 $0.0002 January 24, 2018 $8,250 55,000,000 $0.00015 February 1, 2018 $7,220 57,760,000 $0.000125 Subsequent Total $44,875 260,410,000 | Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $2,197 488,316 $ 0.00450 April 4, 2016 $4,847 862,500 $ 0.00562 April 7, 2016 $1,750 486,111 $ 0.00360 April 14, 2016 $4,158 962,500 $ 0.00432 April 15, 2016 $1,318 488,311 $ 0.00270 April 26, 2016 $1,705 631,489 $ 0.00270 May 4, 2016 $2,067 485,901 $ 0.00426 May 31, 2016 $ 828 230,003 $ 0.00360 June 2, 2016 $9,120 1,500,000 $ 0.00608 June 2, 2016 $4,401 1,467,017 $ 0.00300 June 14, 2016 $5,847 1,461,795 $ 0.00400 June 17,2016 $5,691 1,422,808 $ 0.00400 June 29, 2016 $6,580 1,063,518 $ 0.00618 August 23, 2016 $2,567 1,106,487 $ 0.00232 August 29, 2016 $2,570 1,107,806 $ 0.00232 September 6, 2016 $2,547 1,097,634 $ 0.00232 September 20, 2016 $2,443 1,263,383 $ 0.00194 September 26, 2016 $2,946 1,269,672 $ 0.00232 September 28, 2016 $2,947 1,270,172 $ 0.00232 September 30, 2016 $3,949 2,553,336 $ 0.00154 October 7, 2016 $3,381 2,914,578 $ 0.00116 October 14, 2016 $3,380 2,913,784 $ 0.00116 October 21, 2016 $3,385 2,917,784 $ 0.00116 October 26, 2016 $3,382 2,915,828 $ 0.00116 October 31, 2016 $5,037 4,341,852 $ 0.00116 November 7 , 2016 $5,015 4,323,647 $ 0.00116 November 22, 2016 $5,513 4,753,008 $ 0.00116 November 29, 2016 $5,515 4,754,647 $ 0.00116 December 6, 2016 $4,058 3,497,965 $ 0.00116 January 10, 2017 $6,301 6,301,150 $ 0.00100 February 22, 2017 $4,290 3,575,000 $ 0.00120 March 13, 2017 $4,080 3,400,000 $ 0.00120 March 21, 2017 $4,920 4,100,000 $ 0.00120 March 22, 2017 $5,160 4,300,000 $ 0.00120 March 24, 2017 $5,460 4,550,000 $ 0.00120 March 30, 2017 $5,645 4,800,000 $ 0.00118 March 31, 2017 $5,939 5,050,000 $ 0.00118 March 31, 2017 Total $150,939 90,628,002 | Date Debt/Interest Converted Common Stock Issued Price per Share April 5, 2017 $6,233 5,300,000 $0.00118 April 10, 2017 $6,586 5,600,000 $0.00118 April 11, 2017 $6,880 5,850,000 $0.00118 April 18, 2017 $7,291 6,200,000 $0.00118 April 20, 2017 $7,644 6,500,000 $0.00118 April 21, 2017 $16,464 14,000,000 $0.00118 April 25, 2017 $17,287 14,700,000 $0.00118 April 26, 2017 $26,600 26,600,000 $0.00100 May 1, 2017 $8,700 14,500,000 $0.00060 June 13, 2017 $1,200 10,000,000 $0.00012 June 16, 2017 $1,930 19,299,400 $0.00010 June 16, 2017 $1,300 11,000,000 $0.00012 June 20, 2017 $1,392 11,600,000 $0.00012 June 21, 2017 $2,314 23,139,900 $0.00010 June 22, 2017 $1,590 13,250,000 $0.00012 June 22, 2017 $1,470 12,250,000 $0.00012 June 26, 2017 $1,800 15,000,000 $0.00012 June 29, 2017 $1,980 16,500,000 $0.00012 July 3, 2017 $2,088 17,400,000 $0.00012 July 12, 2017 $2,088 17,400,000 $0.00012 July 13, 2017 $2,484 13,800,000 $0.00018 July 14, 2017 $3,374 19,000,000 $0.00018 July 18, 2017 $3,374 19,000,000 $0.00018 July 20, 2017 $3,582 19,900,000 $0.00018 July 24, 2017 $6,270 20,900,000 $0.0003 July 25, 2017 $6,870 22,900,000 $0.0003 July 28, 2017 $7,200 24,000,000 $0.0003 August 2, 2017 $7,200 24,000,000 $0.0003 August 4, 2017 $9,000 25,000,000 $0.00036 August 8, 2017 $11,119 26,475,000 $0.00042 August 11, 2017 $13,920 29,000,000 $0.00048 August 16, 2017 $12,810 30,500,000 $0.00042 August 22, 2017 $6,709 19,168,058 $0.00035 August 25, 2017 $11,200 32,000,000 $0.00035 August 31, 2017 $9,600 32,000,000 $0.0003 September 7, 2017 $9,900 36,000,000 $0.00028 September 15, 2017 $9,437 37,900,000 $0.00025 September 22, 2017 $9,910 39,800,000 $0.00025 September 28, 2017 $10,408 41,800,000 $0.00025 October 3, 2017 $10,931 43,900,000 $0.00025 October 5, 2017 $7,582 30,448,193 $0.00025 December 31, 2017 Total $295,717 853,580,551 |
Summary of Significant Accoun24
Summary of Significant Accounting Policies (Details Narrative) | 9 Months Ended | 12 Months Ended | ||||
Dec. 31, 2017USD ($)$ / sharesshares | Mar. 31, 2017USD ($)$ / sharesshares | Mar. 31, 2016shares | Mar. 31, 2013$ / sharesshares | Sep. 06, 2013$ / sharesshares | Sep. 05, 2013$ / sharesshares | |
Date Of Incorporation | Aug. 9, 2010 | |||||
Cancellation of loans | $ | ||||||
Common Stock, Shares Authorized | 2,000,000,000 | 2,000,000,000 | 375,030,000 | 375,030,000 | 900,000 | |
Common Stock, Par Value | $ / shares | $ .001 | $ .001 | $ 0.001 | $ 0.001 | $ 0.001 | |
Stock split ratio | 0.05 | 0.01 | 4.1671 | |||
Cash and cash equivalent | $ | $ 3,743 | $ 40,903 | ||||
Reserved common shares | 195,002 | |||||
Computer equipment | 3 years | |||||
Options granted, number of shares | 29,000,000 | 195,000 | ||||
Dilutive Instruments, common stock warrants | 9,446,533 | |||||
Dilutive Instruments, common stock shares | 29,228,627 | |||||
Sale Agmt | ||||||
Date of Agreement | Jul. 19, 2013 | |||||
Cancellation of loans | $ | $ 28,818 | |||||
Shares sold by former officers | 265,646 | |||||
Shares returned to treasury | 250,128 | |||||
Shares agreed to cancel | 131,261 | |||||
Asset Assign Agmt | ||||||
Date of Agreement | Jul. 18, 2013 | |||||
Common Stock, shares issued | 41,384 | |||||
Series A Preferred Stock, shares issued | 6,000,000 | |||||
Stock Value | $ | $ 123,973 | |||||
Termination of agreement | $ | 20,000 | |||||
Additional cash required | $ | $ 2,000,000 |
Property and equipment - Schedu
Property and equipment - Schedule of Property and Equipment (Details) - USD ($) | Dec. 31, 2017 | Mar. 31, 2017 |
Property, Plant and Equipment [Abstract] | ||
Computer equipment | $ 5,160 | $ 5,160 |
Less: accumulated depreciation | (3,935) | (3,035) |
Property and equipment, net | $ 1,225 | $ 2,125 |
Property and Equipment (Details
Property and Equipment (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Mar. 31, 2017 | |
Property And Equipment Details Narrative | |||||
Depreciation expense | $ 313 | $ 431 | $ 899 | $ 1,293 | $ 1,606 |
Computer equipment | 3 years |
Securities Available For Sale (
Securities Available For Sale (Details Narrative) - Collaboration Agmt | Dec. 31, 2017shares |
Securities available for sale | 15,000,000 |
Ownership of Subsidiary | 11.00% |
Intangible Assets (Details Narr
Intangible Assets (Details Narrative) | 9 Months Ended |
Dec. 31, 2017USD ($)shares | |
Asset Assign Agmt | |
Date of Agreement | Jul. 18, 2013 |
Common Stock, shares issued | shares | 41,384 |
Series A Preferred Stock, shares issued | shares | 6,000,000 |
Stock Value | $ 123,973 |
Impaired Assets | 0 |
Asset Development Cost | $ 45,000 |
Asset Assign Agmt #2 | |
Date of Agreement | Oct. 6, 2014 |
Common Stock, shares issued | shares | 110,396 |
Common stock, value | $ 7,904,355 |
Impaired Assets | 0 |
Impairment of intangible asset | $ 82,120 |
Accrued Expenses - Schedule of
Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) | Dec. 31, 2017 | Mar. 31, 2017 |
Payables and Accruals [Abstract] | ||
Wages and taxes | $ 1,140,040 | $ 829,231 |
Accrued interest | 220,770 | 108,552 |
Total accrued expenses | $ 1,360,810 | $ 937,783 |
Related Party Debt and Transa30
Related Party Debt and Transactions (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Mar. 31, 2017 | Mar. 31, 2015 | Mar. 31, 2016 | |
Cancellation of loans | |||||||
Due to related parties | $ 37,024 | 37,024 | $ 49,395 | ||||
Loans and interest received (repaid) from/to related parties | (12,371) | $ (27,319) | |||||
Interest expense, related party | (155) | $ (155) | (463) | $ (385) | |||
Accrued expenses | 1,360,810 | 1,360,810 | 937,783 | ||||
Accounts payable related party | 376,950 | 376,950 | 53,000 | ||||
SH Loan #1 | |||||||
Due Date | Jan. 8, 2016 | ||||||
Loan from related party | $ 6,000 | ||||||
Interest Rate | 8.00% | ||||||
SH Loan #2 | |||||||
Loan from related party | 6,280 | ||||||
Due to related parties | $ 12,280 | $ 12,280 | 12,280 | ||||
Interest Rate | 8.00% | 8.00% | |||||
Interest expense, related party | $ 1,366 | ||||||
Related Party Loans | |||||||
Due to related parties | $ 350 | 350 | |||||
Repayment of loans to related parties | 23,029 | ||||||
Loans and interest received (repaid) from/to related parties | $ 36,300 | ||||||
Accrued expenses | 14,450 | $ 22,200 | |||||
Employment Agmt | |||||||
Date of Agreement | Sep. 6, 2013 | ||||||
Term of Agreement | 2 years | ||||||
Annual Compensation | $ 275,000 | ||||||
Options to purchase | 1,500 | ||||||
Options to purchase, exercise price | $ 40 | ||||||
Bonus | $ 206,250 | ||||||
Earnings | 275,000 | 275,000 | |||||
Accrued Earnings | $ 806,361 | $ 645,945 | |||||
Collaboration Agmt | |||||||
Date of Agreement | Jul. 11, 2017 | ||||||
Securities available for sale | 15,000,000 | 15,000,000 | |||||
Payment for IP | $ 100,000 |
Note Payable (Details Narrative
Note Payable (Details Narrative) | 9 Months Ended |
Dec. 31, 2017USD ($) | |
Note Payable #1 | |
Date of Agreement | May 31, 2016 |
Convertible Note | $ 900,000 |
Interest Rate | 10.00% |
Due Date | Aug. 1, 2017 |
Interest Accrued | $ 142,767 |
Note Payable #2 | |
Date of Agreement | Feb. 21, 2017 |
Convertible Note | $ 20,000 |
Interest Rate | 8.00% |
Due Date | Aug. 21, 2017 |
Interest Accrued | $ 1,372 |
Convertible Note Payable (Detai
Convertible Note Payable (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Mar. 31, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | Mar. 31, 2017 | Mar. 31, 2016 | |
Debt Instrument, Converted Amount | $ 295,721 | $ 109,144 | |||
Convertible Prom Note #15 | |||||
Date of Agreement | Feb. 5, 2015 | ||||
Convertible Note | $ 54,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Nov. 9, 2015 | ||||
Interest Accrued | 0 | ||||
Convertible Note, Balance | 0 | $ 59,799 | $ 47,980 | ||
Debt Instrument, Converted Amount | $ 33,020 | ||||
Common Stock, shares issued | 619,652 | ||||
Fee | Financing | Default | |||
Fee Amount | $ 11,819 | $ 11,819 | $ 27,000 | ||
Convertible Prom Note #18 | |||||
Date of Agreement | Mar. 9, 2015 | ||||
Convertible Note | $ 55,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Jun. 23, 2017 | ||||
Interest Accrued | 0 | 0 | $ 0 | ||
Convertible Note, Balance | 8,838 | 0 | 16,215 | ||
Debt Instrument, Converted Amount | 7,377 | 38,785 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 422 | $ 5,135 | |||
Common Stock, shares issued | 2,324,229 | 2,886,693 | |||
Convertible Prom Note #19 | |||||
Date of Agreement | Mar. 26, 2015 | ||||
Convertible Note | $ 29,680 | ||||
Interest Rate | 8.00% | ||||
Due Date | Mar. 23, 2016 | ||||
Interest Accrued | 4,602 | $ 2,577 | |||
Convertible Note, Balance | 18,751 | ||||
Original Issue Discount | 1,680 | ||||
Debt Instrument, Converted Amount | $ 10,929 | ||||
Common Stock, shares issued | 796,236 | ||||
Convertible Prom Note #21 | |||||
Date of Agreement | May 5, 2015 | ||||
Convertible Note | $ 68,900 | ||||
Interest Rate | 8.00% | ||||
Due Date | May 5, 2016 | ||||
Interest Accrued | 0 | ||||
Convertible Note, Balance | 0 | ||||
Original Issue Discount | $ 3,900 | ||||
Debt Instrument, Converted Amount | 8,461 | 60,439 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 566 | $ 6,839 | |||
Common Stock, shares issued | 906,763 | 44,551,004 | |||
Convertible Prom Note #22 | |||||
Date of Agreement | May 6, 2015 | ||||
Convertible Note | $ 10,500 | ||||
Interest Rate | 8.00% | ||||
Due Date | Feb. 8, 2016 | ||||
Interest Accrued | 0 | ||||
Convertible Note, Balance | $ 20,900 | 0 | $ 15,750 | ||
Fee | Financing | Default | |||
Fee Amount | $ 5,250 | $ 5,150 | $ 5,250 | ||
Convertible Prom Note #24 | |||||
Date of Agreement | Aug. 28, 2015 | ||||
Convertible Note | $ 15,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Aug. 28, 2016 | ||||
Interest Accrued | $ 0 | ||||
Convertible Note, Balance | 0 | ||||
Debt Instrument, Converted Amount | 15,000 | ||||
Debt Instrument, Interest Accrued, Converted Amount | $ 939 | ||||
Common Stock, shares issued | 4,351,619 | ||||
Convertible Prom Note #25 | |||||
Date of Agreement | Sep. 4, 2015 | ||||
Convertible Note | $ 19,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Jun. 4, 2016 | ||||
Interest Accrued | 0 | ||||
Convertible Note, Balance | 0 | $ 20,280 | |||
Fee | Financing | ||||
Fee Amount | 1,280 | $ 1,280 | |||
Convertible Prom Note #26 | |||||
Date of Agreement | Dec. 29, 2015 | ||||
Convertible Note | $ 57,378 | ||||
Interest Rate | 8.00% | ||||
Due Date | Jun. 23, 2017 | ||||
Interest Accrued | 0 | $ 0 | |||
Convertible Note, Balance | $ 0 | 1,609 | |||
Debt Instrument, Converted Amount | 59,934 | ||||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,222 | ||||
Common Stock, shares issued | 1,796,394 | ||||
Fee | Default | ||||
Fee Amount | $ 4,165 | ||||
Convertible Prom Note #27 | |||||
Date of Agreement | Jan. 22, 2016 | ||||
Convertible Note | $ 60,500 | ||||
Interest Rate | 10.00% | ||||
Due Date | Oct. 22, 2016 | ||||
Interest Accrued | $ 0 | ||||
Convertible Note, Balance | $ 0 | ||||
Convertible Prom Note #28 | |||||
Date of Agreement | Feb. 25, 2016 | ||||
Convertible Note | $ 27,500 | ||||
Interest Rate | 8.00% | ||||
Due Date | Feb. 25, 2017 | ||||
Interest Accrued | $ 0 | ||||
Convertible Note, Balance | 0 | ||||
Original Issue Discount, unamortized | 212 | ||||
Debt Instrument, Converted Amount | 16,745 | ||||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,380 | ||||
Common Stock, shares issued | 3,325,000 | ||||
Convertible Prom Note #29 | |||||
Date of Agreement | Mar. 24, 2016 | ||||
Convertible Note | $ 7,500 | ||||
Interest Rate | 8.00% | ||||
Due Date | Mar. 24, 2017 | ||||
Interest Accrued | $ 0 | ||||
Convertible Prom Note #34 | |||||
Date of Agreement | May 25, 2016 | ||||
Convertible Note | $ 30,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | May 25, 2017 | ||||
Interest Accrued | $ 0 | ||||
Convertible Note, Balance | $ 0 | ||||
Fee | Financing | ||||
Fee Amount | 8,107 | $ 8,107 | |||
Convertible Prom Note #30 | |||||
Date of Agreement | Jun. 8, 2016 | ||||
Convertible Note | $ 84,250 | ||||
Interest Rate | 8.00% | ||||
Due Date | Jun. 8, 2017 | ||||
Interest Accrued | $ 0 | ||||
Convertible Note, Balance | $ 0 | ||||
Fee | Financing | ||||
Fee Amount | $ 49,964 | $ 49,964 | |||
Convertible Prom Note #32 | |||||
Date of Agreement | Jun. 23, 2016 | ||||
Convertible Note | $ 56,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Jun. 23, 2017 | ||||
Interest Accrued | $ 6,824 | ||||
Convertible Prom Note #35 | |||||
Date of Agreement | Jul. 7, 2016 | ||||
Convertible Note | $ 58,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Jul. 7, 2017 | ||||
Interest Accrued | $ 3,455 | ||||
Convertible Note, Balance | 29,055 | ||||
Debt Instrument, Converted Amount | 28,945 | ||||
Debt Instrument, Interest Accrued, Converted Amount | $ 1,902 | ||||
Common Stock, shares issued | 69,039,300 | ||||
Convertible Prom Note #36 | |||||
Date of Agreement | Oct. 20, 2016 | ||||
Convertible Note | $ 32,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Oct. 20, 2017 | ||||
Interest Accrued | $ 3,065 | ||||
Convertible Prom Note #37 | |||||
Date of Agreement | Nov. 17, 2016 | ||||
Convertible Note | $ 56,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Jun. 23, 2017 | ||||
Interest Accrued | $ 6,824 | ||||
Convertible Prom Note #38 | |||||
Date of Agreement | Jan. 5, 2017 | ||||
Convertible Note | $ 335,000 | ||||
Interest Rate | 10.00% | ||||
Due Date | Oct. 5, 2017 | ||||
Interest Accrued | $ 31,753 | ||||
Convertible Note, Balance | 0 | ||||
Original Issue Discount | 30,000 | ||||
Convertible Prom Note #39 | |||||
Date of Agreement | Feb. 20, 2017 | ||||
Convertible Note | $ 563,028 | ||||
Interest Rate | 8.00% | ||||
Due Date | Oct. 25, 2017 | ||||
Interest Accrued | 5,799 | ||||
Convertible Note, Balance | 122,086 | ||||
Debt Instrument, Converted Amount | 86,857 | $ 34,370 | |||
Debt Instrument, Interest Accrued, Converted Amount | $ 3,048 | $ 1,124 | |||
Common Stock, shares issued | 179,650,000 | 29,775,000 | |||
Convertible Prom Note #40 | |||||
Date of Agreement | Feb. 21, 2017 | ||||
Convertible Note | $ 15,000 | ||||
Interest Rate | 8.00% | ||||
Due Date | Oct. 25, 2017 | ||||
Interest Accrued | $ 1,029 | ||||
Convertible Prom Note #41 | |||||
Date of Agreement | Feb. 22, 2017 | ||||
Convertible Note | $ 59,799 | ||||
Interest Rate | 10.00% | ||||
Due Date | Oct. 25, 2017 | ||||
Interest Accrued | $ 1,507 | ||||
Convertible Note, Balance | 0 | ||||
Debt Instrument, Converted Amount | 59,799 | ||||
Debt Instrument, Interest Accrued, Converted Amount | 4,795 | ||||
Default Penalty to be recognized | $ 31,407 | ||||
Common Stock, shares issued | 311,043,058 | ||||
Default Penalty to be recognized | $ 31,407 | ||||
Convertible Prom Note #42 | |||||
Date of Agreement | Feb. 22, 2017 | ||||
Convertible Note | $ 20,900 | ||||
Interest Rate | 10.00% | ||||
Due Date | Oct. 22, 2017 | ||||
Interest Accrued | $ 0 | ||||
Convertible Note, Balance | 0 | ||||
Debt Instrument, Converted Amount | 20,900 | ||||
Debt Instrument, Interest Accrued, Converted Amount | 23,913 | ||||
Default Penalty to be recognized | $ 34,156 | ||||
Common Stock, shares issued | 293,848,193 | ||||
Default Penalty to be recognized | $ 34,156 | ||||
Convertible Prom Note #43 | |||||
Date of Agreement | Apr. 4, 2017 | ||||
Convertible Note | $ 71,457 | ||||
Interest Rate | 8.00% | ||||
Due Date | Jan. 8, 2018 | ||||
Interest Accrued | $ 4,244 | ||||
Convertible Prom Note #44 | |||||
Date of Agreement | Apr. 18, 2017 | ||||
Convertible Note | $ 115,000 | ||||
Interest Rate | 10.00% | ||||
Due Date | Jan. 30, 2018 | ||||
Interest Accrued | $ 6,445 | ||||
Original Issue Discount | 11,500 | ||||
Original Issue Discount, unamortized | $ 0 | ||||
Convertible Prom Note #45 | |||||
Date of Agreement | Nov. 3, 2017 | ||||
Convertible Note | $ 34,500 | ||||
Interest Rate | 10.00% | ||||
Due Date | Aug. 3, 2018 | ||||
Interest Accrued | $ 548 | ||||
Original Issue Discount | $ 2,334 | ||||
Convertible Prom Note #46 | |||||
Date of Agreement | Dec. 18, 2017 | ||||
Convertible Note | $ 43,850 | ||||
Interest Rate | 10.00% | ||||
Due Date | Sep. 18, 2018 | ||||
Interest Accrued | $ 156 | ||||
Original Issue Discount | $ 3,650 |
Derivative Liabilities (Details
Derivative Liabilities (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Mar. 31, 2017 | |
Notes to Financial Statements | |||||
Change in value of derivative liability | $ (691,707) | $ 84,508 | $ (1,760,172) | $ (83,946) | |
Derivative expense | (78,350) | $ (170,250) | (327,807) | $ (170,250) | |
Debt Discounts, Conversion Features | 855,130 | 855,130 | |||
Debt Discount, Unamortized | 90,186 | 90,186 | |||
Derivative liabilities | 1,360,706 | 1,360,706 | $ 2,607,959 | ||
Derivative liabilities |
Equity Transactions - Schedule
Equity Transactions - Schedule of Value of Warrants (Details) - Warrant #10 | 9 Months Ended |
Dec. 31, 2017USD ($)$ / shares | |
Date | Mar. 30, 2017 |
Warrants | $ 9,200,000 |
Stock price on grant date | $ / shares | $ 0.002 |
Exercise price | $ / shares | $ 0.002 |
Expected life | 5 years |
Volatility | 120.00% |
Risk-free rate | 1.96% |
Calculated value | $ 15,278 |
Fair value allocation of proceeds | $ 45,466 |
Equity Transactions - Schedul35
Equity Transactions - Schedule of Warrant Activity (Details) - $ / shares | 9 Months Ended | 12 Months Ended |
Dec. 31, 2017 | Mar. 31, 2017 | |
Accounting Policies [Abstract] | ||
Beginning Balance, Issued Warrants | 9,446,533 | |
Beginning Balance, Average Exercise Price | $ 0.102 | |
Exercised, Warrants | ||
Exercised, Average Exercise Price | ||
Expired Warrants | ||
Expired Average Exercise Price | ||
Ending Balance, Issued Warrants | 9,446,533 | 9,446,533 |
Ending Balance, Average Exercise Price | $ 0.102 | $ 0.102 |
Equity Transactions - Schedul36
Equity Transactions - Schedule of Value of Options (Details) | 9 Months Ended |
Dec. 31, 2017USD ($)$ / sharesshares | |
Stock Option 7 | |
Date of Issuance | Apr. 6, 2015 |
Options | shares | 102,000 |
Stock price on grant date | $ 1.60 |
Exercise price | 1.60 |
Exercise price, modified | $ 0.20 |
Expected life | 5 years |
Volatility | 99.00% |
Risk-free rate | 1.31% |
Calculated value | $ | $ 120,778 |
Modified value | $ | $ 151,221 |
Stock Option 8 | |
Date of Issuance | Jun. 9, 2015 |
Options | shares | 50,000 |
Stock price on grant date | $ 0.40 |
Exercise price | 0.40 |
Exercise price, modified | $ 0.20 |
Expected life | 5 years |
Volatility | 99.00% |
Risk-free rate | 1.74% |
Calculated value | $ | $ 14,838 |
Modified value | $ | $ 16,347 |
Stock Option 9 | |
Date of Issuance | Dec. 15, 2015 |
Options | shares | 43,000 |
Stock price on grant date | $ 0.20 |
Exercise price | 0.20 |
Exercise price, modified | $ 0.20 |
Expected life | 5 years |
Volatility | 84.00% |
Risk-free rate | 1.70% |
Calculated value | $ | $ 5,736 |
Modified value | $ | $ 5,736 |
Stock Option 10 | |
Date of Issuance | Mar. 30, 2017 |
Options | shares | 29,000,000 |
Stock price on grant date | $ 0.002 |
Exercise price | $ 0.002 |
Expected life | 5 years |
Volatility | 120.00% |
Risk-free rate | 1.93% |
Calculated value | $ | $ 48,017 |
Modified value | $ | $ 48,017 |
Equity Transactions - Schedul37
Equity Transactions - Schedule of Option Activity (Details) - shares | 9 Months Ended | 12 Months Ended | |
Dec. 31, 2017 | Mar. 31, 2017 | Mar. 31, 2016 | |
Accounting Policies [Abstract] | |||
Beginning Balance, number of shares | 29,228,627 | ||
Beginning Balance, weighted average exercise price | 0.004 | ||
Options granted, number of shares | 29,000,000 | 195,000 | |
Options exercised, number of shares | |||
Options exercised, weighted average exercise price | |||
Options expired, number of shares | |||
Options expired, weighted average exercise price | |||
Ending Balance, number of shares | 29,228,627 | 29,228,627 | |
Ending Balance, weighted average exercise price | 0.004 | 0.004 |
Equity Transactions (Details Na
Equity Transactions (Details Narrative) | 9 Months Ended | 12 Months Ended | ||||||
Dec. 31, 2017USD ($)$ / sharesshares | Dec. 31, 2016USD ($) | Mar. 31, 2017USD ($)$ / sharesshares | Mar. 31, 2016shares | Mar. 31, 2013$ / sharesshares | Sep. 06, 2013$ / sharesshares | Sep. 05, 2013$ / sharesshares | Jul. 18, 2013shares | |
Common Stock, Shares Authorized | shares | 2,000,000,000 | 2,000,000,000 | 375,030,000 | 375,030,000 | 900,000 | |||
Common Stock, Par Value | $ / shares | $ .001 | $ .001 | $ 0.001 | $ 0.001 | $ 0.001 | |||
Preferred Stock, Shares Authorized | shares | 10,000,000 | 10,000,000 | ||||||
Preferred Stock, Par Value | $ / shares | $ .001 | $ .001 | ||||||
Series A Preferred Stock, Designated | shares | 6,000,000 | |||||||
Common Stock, Issued | shares | 955,027,813 | 101,446,215 | ||||||
Preferred Stock, Issued | shares | 6,000,000 | 6,000,000 | ||||||
Stock split ratio | 0.05 | 0.01 | 4.1671 | |||||
Options granted, number of shares | shares | 29,000,000 | 195,000 | ||||||
Debt Instrument, Converted Amount | $ | $ 295,721 | $ 109,144 | ||||||
Stock-based compensation | $ | ||||||||
Common Stock Issued, Convertible Debt, Shares | shares | 853,580,551 | |||||||
Adjustment to APIC | $ | $ 557,863 | |||||||
Common stock to be issued | $ | $ 100,000 | |||||||
Stock Sub Agmt | ||||||||
Date of Agreement | Oct. 16, 2017 | |||||||
Warrants | $ | $ 333,333,333 | |||||||
Exercise price | $ / shares | $ 0.0003 | |||||||
Expected life | 5 years | |||||||
Common Stock, Subscribed but Unissued | shares | 333,333,333 | |||||||
Common stock to be issued | $ | $ 100,000 | |||||||
2013 Stock Option Plan Amendment | ||||||||
Stock-based compensation | $ | $ 50,448 | |||||||
2013 Stock Option Plan Amdt #2 | ||||||||
Date of Agreement | Apr. 6, 2015 | |||||||
Options granted, number of shares | shares | 135,627 | |||||||
Exercise price | $ / shares | $ 1.60 | |||||||
Stock-based compensation | $ | $ 9,316 | |||||||
2013 Stock Option Plan Amdt #3 | ||||||||
Date of Agreement | Aug. 4, 2015 | |||||||
Options granted, number of shares | shares | 185,627 | |||||||
Exercise price | $ / shares | $ 0.40 | |||||||
Stock-based compensation | $ | $ 47,463 | |||||||
Debt Conversion #65 | ||||||||
Date of Issuance | Jan. 4, 2016 | |||||||
Common Stock, shares issued | shares | 161,161 | |||||||
Common Stock, price per share | $ / shares | $ .12000 | |||||||
Debt Instrument, Converted Amount | $ | $ 19,339 | |||||||
Debt Conversion #89 | ||||||||
Date of Issuance | Apr. 1, 2016 | |||||||
Common Stock, shares issued | shares | 488,316 | |||||||
Common Stock, price per share | $ / shares | $ .00450 | |||||||
Debt Instrument, Converted Amount | $ | $ 2,197 | |||||||
Debt Conversion #90 | ||||||||
Date of Issuance | Apr. 4, 2016 | |||||||
Common Stock, shares issued | shares | 862,500 | |||||||
Common Stock, price per share | $ / shares | $ .00562 | |||||||
Debt Instrument, Converted Amount | $ | $ 4,847 | |||||||
Debt Conversion #91 | ||||||||
Date of Issuance | Apr. 7, 2016 | |||||||
Common Stock, shares issued | shares | 486,111 | |||||||
Common Stock, price per share | $ / shares | $ .00360 | |||||||
Debt Instrument, Converted Amount | $ | $ 1,750 | |||||||
Debt Conversion #92 | ||||||||
Date of Issuance | Apr. 14, 2016 | |||||||
Common Stock, shares issued | shares | 962,500 | |||||||
Common Stock, price per share | $ / shares | $ .00432 | |||||||
Debt Instrument, Converted Amount | $ | $ 4,158 | |||||||
Debt Conversion #93 | ||||||||
Date of Issuance | Apr. 15, 2016 | |||||||
Common Stock, shares issued | shares | 488,311 | |||||||
Common Stock, price per share | $ / shares | $ .00270 | |||||||
Debt Instrument, Converted Amount | $ | $ 1,318 | |||||||
Debt Conversion #94 | ||||||||
Date of Issuance | Apr. 26, 2016 | |||||||
Common Stock, shares issued | shares | 631,489 | |||||||
Common Stock, price per share | $ / shares | $ .00270 | |||||||
Debt Instrument, Converted Amount | $ | $ 1,705 | |||||||
Debt Conversion #95 | ||||||||
Date of Issuance | May 4, 2016 | |||||||
Common Stock, shares issued | shares | 485,901 | |||||||
Common Stock, price per share | $ / shares | $ .00426 | |||||||
Debt Instrument, Converted Amount | $ | $ 2,067 | |||||||
Debt Conversion #96 | ||||||||
Date of Issuance | May 31, 2016 | |||||||
Common Stock, shares issued | shares | 230,003 | |||||||
Common Stock, price per share | $ / shares | $ .00360 | |||||||
Debt Instrument, Converted Amount | $ | $ 828 | |||||||
Debt Conversion #97 | ||||||||
Date of Issuance | Jun. 2, 2016 | |||||||
Common Stock, shares issued | shares | 1,500,000 | |||||||
Common Stock, price per share | $ / shares | $ .00608 | |||||||
Debt Instrument, Converted Amount | $ | $ 9,120 | |||||||
Debt Conversion #98 | ||||||||
Date of Issuance | Jun. 2, 2016 | |||||||
Common Stock, shares issued | shares | 1,467,017 | |||||||
Common Stock, price per share | $ / shares | $ .00300 | |||||||
Debt Instrument, Converted Amount | $ | $ 4,401 | |||||||
Debt Conversion #99 | ||||||||
Date of Issuance | Jun. 14, 2016 | |||||||
Common Stock, shares issued | shares | 1,461,795 | |||||||
Common Stock, price per share | $ / shares | $ .00400 | |||||||
Debt Instrument, Converted Amount | $ | $ 5,847 | |||||||
Debt Conversion #100 | ||||||||
Date of Issuance | Jun. 17, 2016 | |||||||
Common Stock, shares issued | shares | 1,422,808 | |||||||
Common Stock, price per share | $ / shares | $ .00400 | |||||||
Debt Instrument, Converted Amount | $ | $ 5,691 | |||||||
Debt Conversion #101 | ||||||||
Date of Issuance | Jun. 29, 2017 | |||||||
Common Stock, shares issued | shares | 1,063,518 | |||||||
Common Stock, price per share | $ / shares | $ .00618 | |||||||
Debt Instrument, Converted Amount | $ | $ 6,580 | |||||||
Debt Conversion #102 | ||||||||
Date of Issuance | Aug. 23, 2016 | |||||||
Common Stock, shares issued | shares | 1,106,487 | |||||||
Common Stock, price per share | $ / shares | $ .00232 | |||||||
Debt Instrument, Converted Amount | $ | $ 2,567 | |||||||
Debt Conversion #103 | ||||||||
Date of Issuance | Aug. 29, 2016 | |||||||
Common Stock, shares issued | shares | 1,107,806 | |||||||
Common Stock, price per share | $ / shares | $ .00232 | |||||||
Debt Instrument, Converted Amount | $ | $ 2,570 | |||||||
Debt Conversion #104 | ||||||||
Date of Issuance | Sep. 6, 2016 | |||||||
Common Stock, shares issued | shares | 1,097,634 | |||||||
Common Stock, price per share | $ / shares | $ .00232 | |||||||
Debt Instrument, Converted Amount | $ | $ 2,547 | |||||||
Debt Conversion #105 | ||||||||
Date of Issuance | Sep. 20, 2016 | |||||||
Common Stock, shares issued | shares | 1,263,383 | |||||||
Common Stock, price per share | $ / shares | $ .00194 | |||||||
Debt Instrument, Converted Amount | $ | $ 2,443 | |||||||
Debt Conversion #106 | ||||||||
Date of Issuance | Sep. 26, 2016 | |||||||
Common Stock, shares issued | shares | 1,269,672 | |||||||
Common Stock, price per share | $ / shares | $ .00232 | |||||||
Debt Instrument, Converted Amount | $ | $ 2,946 | |||||||
Debt Conversion #107 | ||||||||
Date of Issuance | Sep. 28, 2016 | |||||||
Common Stock, shares issued | shares | 1,270,172 | |||||||
Common Stock, price per share | $ / shares | $ .00232 | |||||||
Debt Instrument, Converted Amount | $ | $ 2,947 | |||||||
Debt Conversion #108 | ||||||||
Date of Issuance | Sep. 30, 2016 | |||||||
Common Stock, shares issued | shares | 2,553,336 | |||||||
Common Stock, price per share | $ / shares | $ .00154 | |||||||
Debt Instrument, Converted Amount | $ | $ 3,949 | |||||||
Debt Conversion #109 | ||||||||
Date of Issuance | Oct. 7, 2016 | |||||||
Common Stock, shares issued | shares | 2,914,578 | |||||||
Common Stock, price per share | $ / shares | $ .00116 | |||||||
Debt Instrument, Converted Amount | $ | $ 3,381 | |||||||
Debt Conversion #110 | ||||||||
Date of Issuance | Oct. 14, 2016 | |||||||
Common Stock, shares issued | shares | 2,913,784 | |||||||
Common Stock, price per share | $ / shares | $ .00116 | |||||||
Debt Instrument, Converted Amount | $ | $ 3,380 | |||||||
Debt Conversion #111 | ||||||||
Date of Issuance | Oct. 21, 2016 | |||||||
Common Stock, shares issued | shares | 2,917,784 | |||||||
Common Stock, price per share | $ / shares | $ .00116 | |||||||
Debt Instrument, Converted Amount | $ | $ 3,385 | |||||||
Debt Conversion #112 | ||||||||
Date of Issuance | Oct. 26, 2016 | |||||||
Common Stock, shares issued | shares | 2,915,828 | |||||||
Common Stock, price per share | $ / shares | $ .00116 | |||||||
Debt Instrument, Converted Amount | $ | $ 3,382 | |||||||
Debt Conversion #113 | ||||||||
Date of Issuance | Oct. 31, 2016 | |||||||
Common Stock, shares issued | shares | 4,341,853 | |||||||
Common Stock, price per share | $ / shares | $ .00116 | |||||||
Debt Instrument, Converted Amount | $ | $ 5,037 | |||||||
Debt Conversion #114 | ||||||||
Date of Issuance | Nov. 7, 2016 | |||||||
Common Stock, shares issued | shares | 4,323,647 | |||||||
Common Stock, price per share | $ / shares | $ .00116 | |||||||
Debt Instrument, Converted Amount | $ | $ 5,015 | |||||||
Debt Conversion #115 | ||||||||
Date of Issuance | Nov. 22, 2016 | |||||||
Common Stock, shares issued | shares | 4,753,009 | |||||||
Common Stock, price per share | $ / shares | $ .00116 | |||||||
Debt Instrument, Converted Amount | $ | $ 5,513 | |||||||
Debt Conversion #116 | ||||||||
Date of Issuance | Nov. 29, 2016 | |||||||
Common Stock, shares issued | shares | 4,754,647 | |||||||
Common Stock, price per share | $ / shares | $ .00116 | |||||||
Debt Instrument, Converted Amount | $ | $ 5,515 | |||||||
Debt Conversion #117 | ||||||||
Date of Issuance | Dec. 6, 2016 | |||||||
Common Stock, shares issued | shares | 3,497,966 | |||||||
Common Stock, price per share | $ / shares | $ .00116 | |||||||
Debt Instrument, Converted Amount | $ | $ 4,058 | |||||||
Debt Conversion #118 | ||||||||
Date of Issuance | Jan. 10, 2017 | |||||||
Common Stock, shares issued | shares | 6,301,150 | |||||||
Common Stock, price per share | $ / shares | $ 0.00100 | |||||||
Debt Instrument, Converted Amount | $ | $ 6,301 | |||||||
Debt Conversion #119 | ||||||||
Date of Issuance | Feb. 22, 2017 | |||||||
Common Stock, shares issued | shares | 3,575,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00120 | |||||||
Debt Instrument, Converted Amount | $ | $ 4,290 | |||||||
Debt Conversion #120 | ||||||||
Date of Issuance | Mar. 13, 2017 | |||||||
Common Stock, shares issued | shares | 3,400,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00120 | |||||||
Debt Instrument, Converted Amount | $ | $ 4,080 | |||||||
Debt Conversion #121 | ||||||||
Date of Issuance | Mar. 21, 2017 | |||||||
Common Stock, shares issued | shares | 4,100,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00120 | |||||||
Debt Instrument, Converted Amount | $ | $ 4,920 | |||||||
Debt Conversion #122 | ||||||||
Date of Issuance | Mar. 22, 2017 | |||||||
Common Stock, shares issued | shares | 4,300,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00120 | |||||||
Debt Instrument, Converted Amount | $ | $ 5,160 | |||||||
Debt Conversion #123 | ||||||||
Date of Issuance | Mar. 24, 2017 | |||||||
Common Stock, shares issued | shares | 4,550,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00120 | |||||||
Debt Instrument, Converted Amount | $ | $ 5,460 | |||||||
Debt Conversion #124 | ||||||||
Date of Issuance | Mar. 30, 2017 | |||||||
Common Stock, shares issued | shares | 4,800,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00118 | |||||||
Debt Instrument, Converted Amount | $ | $ 5,645 | |||||||
Debt Conversion #125 | ||||||||
Date of Issuance | Mar. 31, 2017 | |||||||
Common Stock, shares issued | shares | 5,050,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00118 | |||||||
Debt Instrument, Converted Amount | $ | $ 5,939 | |||||||
Debt Conversion #126 | ||||||||
Date of Issuance | Apr. 5, 2017 | |||||||
Common Stock, shares issued | shares | 5,300,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00118 | |||||||
Debt Instrument, Converted Amount | $ | $ 6,233 | |||||||
Debt Conversion #127 | ||||||||
Date of Issuance | Apr. 10, 2017 | |||||||
Common Stock, shares issued | shares | 5,600,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00118 | |||||||
Debt Instrument, Converted Amount | $ | $ 6,586 | |||||||
Debt Conversion #128 | ||||||||
Date of Issuance | Apr. 11, 2017 | |||||||
Common Stock, shares issued | shares | 5,850,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00118 | |||||||
Debt Instrument, Converted Amount | $ | $ 6,880 | |||||||
Debt Conversion #129 | ||||||||
Date of Issuance | Apr. 18, 2017 | |||||||
Common Stock, shares issued | shares | 6,200,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00118 | |||||||
Debt Instrument, Converted Amount | $ | $ 7,291 | |||||||
Debt Conversion #130 | ||||||||
Date of Issuance | Apr. 20, 2017 | |||||||
Common Stock, shares issued | shares | 6,500,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00118 | |||||||
Debt Instrument, Converted Amount | $ | $ 7,644 | |||||||
Debt Conversion #131 | ||||||||
Date of Issuance | Apr. 21, 2017 | |||||||
Common Stock, shares issued | shares | 14,000,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00118 | |||||||
Debt Instrument, Converted Amount | $ | $ 16,464 | |||||||
Debt Conversion #132 | ||||||||
Date of Issuance | Apr. 25, 2017 | |||||||
Common Stock, shares issued | shares | 14,700,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00118 | |||||||
Debt Instrument, Converted Amount | $ | $ 17,287 | |||||||
Debt Conversion #133 | ||||||||
Date of Issuance | Apr. 26, 2017 | |||||||
Common Stock, shares issued | shares | 26,600,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.001 | |||||||
Debt Instrument, Converted Amount | $ | $ 26,600 | |||||||
Debt Conversion #134 | ||||||||
Date of Issuance | May 1, 2017 | |||||||
Common Stock, shares issued | shares | 14,500,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00060 | |||||||
Debt Instrument, Converted Amount | $ | $ 8,700 | |||||||
Debt Conversion #135 | ||||||||
Date of Issuance | Jun. 13, 2017 | |||||||
Common Stock, shares issued | shares | 10,000,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00012 | |||||||
Debt Instrument, Converted Amount | $ | $ 1,200 | |||||||
Debt Conversion #136 | ||||||||
Date of Issuance | Jun. 16, 2017 | |||||||
Common Stock, shares issued | shares | 11,000,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00010 | |||||||
Debt Instrument, Converted Amount | $ | $ 1,930 | |||||||
Debt Conversion #137 | ||||||||
Date of Issuance | Jun. 16, 2017 | |||||||
Common Stock, shares issued | shares | 19,299,400 | |||||||
Common Stock, price per share | $ / shares | $ 0.00012 | |||||||
Debt Instrument, Converted Amount | $ | $ 1,300 | |||||||
Debt Conversion #138 | ||||||||
Date of Issuance | Jun. 20, 2017 | |||||||
Common Stock, shares issued | shares | 11,600,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00012 | |||||||
Debt Instrument, Converted Amount | $ | $ 1,382 | |||||||
Debt Conversion #139 | ||||||||
Date of Issuance | Jun. 21, 2017 | |||||||
Common Stock, shares issued | shares | 23,139,900 | |||||||
Common Stock, price per share | $ / shares | $ 0.00010 | |||||||
Debt Instrument, Converted Amount | $ | $ 2,314 | |||||||
Debt Conversion #140 | ||||||||
Date of Issuance | Jun. 22, 2017 | |||||||
Common Stock, shares issued | shares | 12,250,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00012 | |||||||
Debt Instrument, Converted Amount | $ | $ 1,590 | |||||||
Debt Conversion #141 | ||||||||
Date of Issuance | Jun. 22, 2017 | |||||||
Common Stock, shares issued | shares | 13,250,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00012 | |||||||
Debt Instrument, Converted Amount | $ | $ 1,470 | |||||||
Debt Conversion #142 | ||||||||
Date of Issuance | Jun. 26, 2017 | |||||||
Common Stock, shares issued | shares | 15,000,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00012 | |||||||
Debt Instrument, Converted Amount | $ | $ 1,800 | |||||||
Debt Conversion #143 | ||||||||
Date of Issuance | Jun. 29, 2017 | |||||||
Common Stock, shares issued | shares | 16,500,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00012 | |||||||
Debt Instrument, Converted Amount | $ | $ 1,980 | |||||||
Debt Conversion #144 | ||||||||
Date of Issuance | Jul. 3, 2017 | |||||||
Common Stock, shares issued | shares | 17,400,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00012 | |||||||
Debt Instrument, Converted Amount | $ | $ 2,088 | |||||||
Debt Conversion #145 | ||||||||
Date of Issuance | Jul. 12, 2017 | |||||||
Common Stock, shares issued | shares | 17,400,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00012 | |||||||
Debt Instrument, Converted Amount | $ | $ 2,088 | |||||||
Debt Conversion #146 | ||||||||
Date of Issuance | Jul. 13, 2017 | |||||||
Common Stock, shares issued | shares | 13,800,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00018 | |||||||
Debt Instrument, Converted Amount | $ | $ 2,484 | |||||||
Debt Conversion #147 | ||||||||
Date of Issuance | Jul. 14, 2017 | |||||||
Common Stock, shares issued | shares | 19,000,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00018 | |||||||
Debt Instrument, Converted Amount | $ | $ 3,374 | |||||||
Debt Conversion #148 | ||||||||
Date of Issuance | Jul. 3, 2017 | |||||||
Common Stock, shares issued | shares | 19,000,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00018 | |||||||
Debt Instrument, Converted Amount | $ | $ 3,374 | |||||||
Debt Conversion #149 | ||||||||
Date of Issuance | Jul. 20, 2017 | |||||||
Common Stock, shares issued | shares | 19,900,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00018 | |||||||
Debt Instrument, Converted Amount | $ | $ 3,582 | |||||||
Debt Conversion #150 | ||||||||
Date of Issuance | Jul. 24, 2017 | |||||||
Common Stock, shares issued | shares | 20,900,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.0003 | |||||||
Debt Instrument, Converted Amount | $ | $ 6,270 | |||||||
Debt Conversion #151 | ||||||||
Date of Issuance | Jul. 25, 2017 | |||||||
Common Stock, shares issued | shares | 22,900,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.0003 | |||||||
Debt Instrument, Converted Amount | $ | $ 6,870 | |||||||
Debt Conversion #152 | ||||||||
Date of Issuance | Jul. 28, 2017 | |||||||
Common Stock, shares issued | shares | 24,000,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.0003 | |||||||
Debt Instrument, Converted Amount | $ | $ 7,200 | |||||||
Debt Conversion #153 | ||||||||
Date of Issuance | Aug. 2, 2017 | |||||||
Common Stock, shares issued | shares | 24,000,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.0003 | |||||||
Debt Instrument, Converted Amount | $ | $ 7,200 | |||||||
Debt Conversion #154 | ||||||||
Date of Issuance | Aug. 4, 2017 | |||||||
Common Stock, shares issued | shares | 25,000,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00036 | |||||||
Debt Instrument, Converted Amount | $ | $ 9,000 | |||||||
Debt Conversion #155 | ||||||||
Date of Issuance | Aug. 8, 2017 | |||||||
Common Stock, shares issued | shares | 26,475,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00042 | |||||||
Debt Instrument, Converted Amount | $ | $ 11,119 | |||||||
Debt Conversion #156 | ||||||||
Date of Issuance | Aug. 11, 2017 | |||||||
Common Stock, shares issued | shares | 29,000,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00048 | |||||||
Debt Instrument, Converted Amount | $ | $ 13,920 | |||||||
Debt Conversion #157 | ||||||||
Date of Issuance | Aug. 16, 2017 | |||||||
Common Stock, shares issued | shares | 30,500,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00042 | |||||||
Debt Instrument, Converted Amount | $ | $ 12,810 | |||||||
Debt Conversion #158 | ||||||||
Date of Issuance | Aug. 22, 2017 | |||||||
Common Stock, shares issued | shares | 19,168,058 | |||||||
Common Stock, price per share | $ / shares | $ 0.00035 | |||||||
Debt Instrument, Converted Amount | $ | $ 6,709 | |||||||
Debt Conversion #159 | ||||||||
Date of Issuance | Aug. 25, 2017 | |||||||
Common Stock, shares issued | shares | 32,000,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00035 | |||||||
Debt Instrument, Converted Amount | $ | $ 11,200 | |||||||
Debt Conversion #160 | ||||||||
Date of Issuance | Aug. 31, 2017 | |||||||
Common Stock, shares issued | shares | 32,000,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.0003 | |||||||
Debt Instrument, Converted Amount | $ | $ 9,600 | |||||||
Debt Conversion #161 | ||||||||
Date of Issuance | Sep. 7, 2017 | |||||||
Common Stock, shares issued | shares | 36,000,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00028 | |||||||
Debt Instrument, Converted Amount | $ | $ 9,900 | |||||||
Debt Conversion #162 | ||||||||
Date of Issuance | Sep. 15, 2017 | |||||||
Common Stock, shares issued | shares | 37,900,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00025 | |||||||
Debt Instrument, Converted Amount | $ | $ 9,437 | |||||||
Debt Conversion #163 | ||||||||
Date of Issuance | Sep. 22, 2017 | |||||||
Common Stock, shares issued | shares | 39,800,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00025 | |||||||
Debt Instrument, Converted Amount | $ | $ 9,910 | |||||||
Debt Conversion #164 | ||||||||
Date of Issuance | Sep. 28, 2017 | |||||||
Common Stock, shares issued | shares | 41,800,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00025 | |||||||
Debt Instrument, Converted Amount | $ | $ 10,408 | |||||||
Debt Conversion #165 | ||||||||
Date of Issuance | Oct. 3, 2017 | |||||||
Common Stock, shares issued | shares | 43,900,000 | |||||||
Common Stock, price per share | $ / shares | $ 0.00025 | |||||||
Debt Instrument, Converted Amount | $ | $ 10,931 | |||||||
Debt Conversion #166 | ||||||||
Date of Issuance | Oct. 5, 2017 | |||||||
Common Stock, shares issued | shares | 30,448,193 | |||||||
Common Stock, price per share | $ / shares | $ 0.00025 | |||||||
Debt Instrument, Converted Amount | $ | $ 7,582 | |||||||
Warrant #10 | ||||||||
Exercise Date | Mar. 30, 2017 | |||||||
Warrants | $ | $ 9,200,000 | |||||||
Stock price on grant date | $ / shares | $ 0.002 | |||||||
Exercise price | $ / shares | $ 0.002 | |||||||
Expected life | 5 years |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) | 9 Months Ended |
Dec. 31, 2017USD ($)shares | |
Monthly Rent | $ 2,800 |
Contract | |
Date of Agreement | Jul. 8, 2016 |
Contract Duration | 27 months |
Contract Committment Value | $ 193,255 |
CannCodex | |
Date of Agreement | Apr. 1, 2017 |
Shares issued for services | shares | 78,000,000 |
Loan payable | $ 15,300 |
Subsequent Event (Details Narra
Subsequent Event (Details Narrative) | 2 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||
Feb. 28, 2018USD ($)$ / sharesshares | Dec. 31, 2017USD ($)$ / sharesshares | Dec. 31, 2016USD ($) | Dec. 31, 2017USD ($)$ / sharesshares | Dec. 31, 2016USD ($) | Mar. 31, 2016 | Mar. 31, 2013$ / sharesshares | Mar. 31, 2017USD ($)$ / sharesshares | Sep. 06, 2013$ / sharesshares | Sep. 05, 2013$ / sharesshares | |
Debt Instrument, Converted Amount | $ 295,721 | $ 109,144 | ||||||||
Common Stock, Par Value | $ / shares | $ .001 | $ .001 | $ 0.001 | $ .001 | $ 0.001 | $ 0.001 | ||||
Common Stock, Shares Authorized | shares | 2,000,000,000 | 2,000,000,000 | 375,030,000 | 2,000,000,000 | 375,030,000 | 900,000 | ||||
Stock split ratio | 0.05 | 0.01 | 4.1671 | |||||||
Accrued expenses | $ 1,360,810 | $ 1,360,810 | $ 937,783 | |||||||
Consulting expenses | $ 21,625 | $ 10,325 | $ 121,625 | $ 26,400 | ||||||
Convertible Prom Note #47 | ||||||||||
Date of Agreement | Jan. 10, 2018 | |||||||||
Convertible Note | $ 67,500 | |||||||||
Interest Rate | 10.00% | |||||||||
Due Date | Oct. 10, 2018 | |||||||||
Debt Conversion #167 | ||||||||||
Date of Issuance | Jan. 2, 2018 | |||||||||
Debt Instrument, Converted Amount | $ 9,530 | |||||||||
Common Stock, shares issued | shares | 47,650,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.0002 | |||||||||
Debt Conversion #168 | ||||||||||
Date of Issuance | Jan. 12, 2018 | |||||||||
Debt Instrument, Converted Amount | $ 10,000 | |||||||||
Common Stock, shares issued | shares | 50,000,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.0002 | |||||||||
Debt Conversion #169 | ||||||||||
Date of Issuance | Jan. 18, 2018 | |||||||||
Debt Instrument, Converted Amount | $ 9,875 | |||||||||
Common Stock, shares issued | shares | 50,000,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.0002 | |||||||||
Debt Conversion #170 | ||||||||||
Date of Issuance | Jan. 24, 2018 | |||||||||
Debt Instrument, Converted Amount | $ 8,250 | |||||||||
Common Stock, shares issued | shares | 55,000,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.00015 | |||||||||
Debt Conversion #171 | ||||||||||
Date of Issuance | Feb. 1, 2018 | |||||||||
Debt Instrument, Converted Amount | $ 7,220 | |||||||||
Common Stock, shares issued | shares | 57,760,000 | |||||||||
Common Stock, price per share | $ / shares | $ 0.000125 |